Basilea Pharmaceutica Ag

Chugai Seiyaku Kabushiki Kaisha

Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Basilea Pharmaceutica Ag, a Swiss Company

Jun Ohwada

Nobuo Shimma

Isao Umeda

Tadakatsu Hayase

Masao Tsukazaki

Hiroshi Fukuda

Masahiro Sakaitani

Nobuhiro Oikawa

Eisaku Mizuguchi

Shigeyasu Ichihara

Hirosato Ebiike

Chikako Murasaki

Noriko Ohga

Daisuke Sawada

Michio Shirai

Hiroki Nishii

Satoshi Niizuma

Yoshiaki Isshiki

Yoshito Nakanishi

Hatsuo Kawada

Sawako Ozawa

Nobuya Ishii

Kenji Morikami

Toshihiro Aoki

Mitsuaki Nakamura

Masami Hasegawa

Toshikazu Yamazaki

Masami Kochi

Kohei Koyama

Miyuki Yoshida

Kimitaka Nakama

Takashi Chiba

Natsuki Kobayashi

Toshiya Sakai

Pingli Liu

Shun Yamamoto

Hiroyuki Shimamura

Aiko Suge

An objective of the present invention is to provide low-molecular-weight compounds that can inhibit Src family kinases. The present invention relates to compounds represented by general formula (I) or pharmacologically acceptable salts thereof. In the formula, Aris optionally substituted Carylene or 5- to 10-membered heteroarylene, and Aris optionally substituted Caryl or 5- to 10-membered heteroaryl. Rand Rare defined as described in the specification.

Aminopyrazole derivatives

A drug is provided that is useful as a preventive or therapeutic for cancer as a result of having superior PI3K inhibitory effects as well as superior stability in the body and water-solubility. A compound, or pharmaceutically acceptable salt thereof, represented by formula (I): [wherein, X represents a single bond, etc.; Y represents a single bond, etc. (provided that X and Y are not simultaneously single bonds); Z represents a hydrogen atom, etc.; m represents an integer of 1 or 2; and Rrepresents a cyclic substituent].

Pyrimidine derivatives as PI3K inhibitor and use thereof

An objective of the present invention is to provide water-soluble prodrugs that can be administered parenterally, and which show excellent water solubility and small interspecies or individual differences and are rapidly converted to the active form by chemical conversion. This invention provides water-soluble prodrugs represented by formula (1), or pharmaceutically acceptable salts, or hydrates or solvates thereof, (wherein,

Water-soluble prodrugs

N-substituted carbamoyloxyalkyl-azolium derivatives which have antifungal activity and are useful for the treatment of fungal diseases.

N-substituted carbamoyloxyalkyl-azolium derivatives

N-substituted carbamoyloxyalkyl-azolium derivatives Which have antifungal activity and are useful for the treatment of fungal diseases.

N-phenyl substituted carbamoyloxyalkyl-azolium derivatives

Intermediates for N-substituted carbamoyloxyalkyl-azolium derivatives

Azoles for treatment of fungal infections

N-Benzylazolium derivatives of the general formula (I), ##STR1## wherein Q is the remainder of an azole compound of the formula II ##STR2## possessing antifungal activity; Z is nitrogen or methine;

N-benzylazolium derivatives

Growing community of inventors

Kamakura, Japan

Jun Ohwada